Genetic polymorphism of CYP2D6 in patients with cardiovascular disease - A cohort study

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 6, 2004, Pages 559-564

  Teh, L K ^a   Zilfalil, B A ^a   Marina, I ^b   Rosemi, B S ^b   Ismail, Rusli ^a,c  

^a SCHOOL OF HEALTH SCIENCES   (Malaysia)

^b General Hospital Kota Bharu   (Malaysia)

^c SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Allele frequency; Cardiovascular disease; CYP2D6 polymorphism; Malaysian

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DNA ISOLATION; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 10844274528     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00600.x     Document Type: Article

References (21)

1. McWilliams JE, Evans AJ, Beer TM, Andersen PE, Cohen JI, Everts EC, Henner WD (2000) Genetic polymorphisms in head and neck cancer risk. Head and Neck, 22, 609-617.
2. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW (1996) Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis, 17, 1923-1929.
3. Agundez JA, Ledesma MC, Benitez J, Ladero JM, Rodriguez-Lescure A, Diaz-Rubio E, Diaz-Rubio M (1995) CYP2D6 genes and risk of liver cancer. Lancet, 345, 830-831.
4. Worrall SF, Corrigan M, High A et al. (1998) Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics, 8, 433-439.
5. Febbo PG, Kantoff PW, Giovannucci E, Brown M, Chang G, Hennekens CH, Stampfer M (1998) Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiology, Biomarkers and Prevention, 7, 1075-1078.
6. Nebert DW (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? American Journal of Human Genetics, 60, 265-271.
7. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet, 2, 1213-1216.
8. Smith CA, Gough AC, Leigh PX et al. (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 339, 1375-1377.
9. Teh LK, Ismail R, Yusof R, Hussein A, Isa MN, Rahman AR (2001) Heterogeneity of the CYP2D6 gene among Malays in Malaysia. Journal of Clinical Pharmacy and therapeutics, 26, 1-7.
10. Bouchardy C, Benhamou S, Dayer P (1996) The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Research, 56, 251-253.
11. Beyeler C, Daly AK, Armstrong M, Astbury C, Bird HA, Idle JR (1994) Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity. Journal of Rheumatology, 21, 1034-1039.
12. Agundez JA, Arroyo R, Ledesma MC et al. (1995) Frequency of allelic variants of CYP2D6 allelic variants in multiple sclerosis. Acta Neurologica Scandinavica, 92, 46A-467.
13. Kurth MC, Kurth JH (1993) Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. American Journal of Medical Genetics, 48, 166-168.
14. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE (1994) Debrisoquine hydroxylase gene polymophism in familial parkinsons' disease. Journal of Neurology, Neurosurgery and Psychiatry, 57, 911-913.
15. Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson's disease. Journal of Pharmacology and Experimental therapeutics, 277, 685-690.
16. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, Wolf CR (1997) Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica, 27, 111-125.
17. Modi S, Gilham DE, Sutcliffe MJ, Lian LY, Primrose WU, Wolf CR, Roberts GC (1997) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry, 36, 4461-4470.
18. Niznik HB, Tyndale RF, Sallee FR, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W (1990) The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding protein. Archives of Biochemistry and Biophysics, 276, 424-432.
19. Warner M, Kohler C, Hansson T, Gustafsson JA (1988) Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. Journal of Neurochemistry, 50, 1057-1065.
20. Werner R (1992) Metabolism of amino acids and related compounds. In: Franz IW, Lohmann FW, Koch G, eds. Essential biochemistry and molecular biology: a comprehensive review. USA: Appleton & Lange, Prentice-Hall International, 115-1138.
21. Franz I-W, Lohman FW, Koch G (1980) Excessive plasma dopamine increase at rest and during exercise after long term beta-adrenoceptor blockade in hypertensive patients. British Heart Journal, 44, 25-29.